News
ONCT
8.55
-2.51%
-0.22
Weekly Report: what happened at ONCT last week (0415-0419)?
Weekly Report · 2d ago
ONCTERNAL ANNOUNCES FIRST PATIENT DOSED IN FOURTH COHORT OF PHASE 1/2 STUDY OF ONCT-534 FOR THE TREATMENT OF R/R METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Reuters · 6d ago
Oppenheimer Reaffirms Their Hold Rating on Oncternal Therapeutics (ONCT)
TipRanks · 04/17 11:45
Weekly Report: what happened at ONCT last week (0408-0412)?
Weekly Report · 04/15 11:54
Oncternal Therapeutics Price Target Cut to $28.00/Share From $30.00 by HC Wainwright & Co.
Dow Jones · 04/15 10:20
Oncternal Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 04/15 10:20
Buy Rating Affirmed for Oncternal Therapeutics with Adjusted Price Target Amid Positive Financials and Upcoming Catalysts
TipRanks · 04/15 10:17
ONCTERNAL THERAPEUTICS, INC. <ONCT.O>: H.C. WAINWRIGHT CUTS TARGET PRICE TO $28 FROM $30
Reuters · 04/15 10:05
Weekly Report: what happened at ONCT last week (0401-0405)?
Weekly Report · 04/08 12:00
Insiders Buying Westlake Chemical Partners And 2 Other Stocks
U.S. Stocks closed mostly lower on Monday. There were a few notable insider trades. When insiders purchase shares, it indicates confidence in the company's prospects or that they view the stock as a bargain. Sow Good Inc. And Westlake Chemical Partners LP made recent notable insider purchases.
Benzinga · 04/02 13:06
Weekly Report: what happened at ONCT last week (0325-0329)?
Weekly Report · 04/01 11:57
Weekly Report: what happened at ONCT last week (0318-0322)?
Weekly Report · 03/25 12:00
Weekly Report: what happened at ONCT last week (0311-0315)?
Weekly Report · 03/18 11:58
Weekly Report: what happened at ONCT last week (0304-0308)?
Weekly Report · 03/11 11:54
Oncternal Therapeutics files for mixed shelf offering
Oncternal Therapeutics files for mixed shelf offering without disclosing the amount. The company filed a prospectus related to a proposed mixed shelf offer. OncternalTherapeutics, Inc. (ONCT) stock. The stock is down 2.7% in the last week.
Seeking Alpha · 03/08 21:52
Analysts Offer Insights on Healthcare Companies: Joint (JYNT), Xtant Medical Holdings (XTNT) and Oncternal Therapeutics (ONCT)
Joint (JYNT) and Xtant Medical Holdings (XTNT) have received a lot of coverage today. Craig-Hallum analyst Jeremy Hamblin reiterated a Hold rating on Joint today. Oncternal Therapeutics (ONCT) has been upgraded to Buy.
TipRanks · 03/08 13:50
Oncternal Therapeutics Inc: Annual report
Press release · 03/08 04:16
Oncternal Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Oncternal Therapeutics Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of $3.11 per share. Revenue rose 73.7% to $297.00 thousand from the same quarter last year. The mean expectation of four analysts was for a loss of £3.07.
Reuters · 03/07 23:33
Press Release: Oncternal Therapeutics Provides -2-
Clinical outcomes may materially change as patient enrollment continues; and other risks described in Oncternal's filings with the U.S. Securities and Exchange Commission. All forward-looking statements in this press release are current only as of the date of this release. The company's shares are trading on the New York Stock Exchange.
Dow Jones · 03/07 21:01
Press Release: Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results. Third dosing cohort fully enrolled for our Phase 1/2 study for ONCT-534. Encouraging response signal at initial dose level in ongoing CAR T cell therapy study for advanced prostate cancer. Cash, cash equivalents and short-term investments totaled $34.3 million as of December 31, 2023.
Dow Jones · 03/07 21:01
More
Webull provides a variety of real-time ONCT stock news. You can receive the latest news about Oncternal Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About ONCT
Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. The Company’s product candidates include ONCT-534, ONCT-808, Zilovertamab, and ONCT-216. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of advanced castration-resistant prostate cancer (CRPC) and other androgen receptor (AR) driven diseases. ONCT-808 is an autologous chimeric antigen receptor (CAR-T) therapy that targets ROR1 for the treatment of hematologic malignancies and solid tumors. Zilovertamab is an investigational, humanized, monoclonal antibody designed to inhibit the function of Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1). Zilovertamab has been evaluated in an investigator-initiated Phase 1b study of zilovertamab in combination with docetaxel in patients with mCRPC.